Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
04/2003
04/08/2003US6545035 Substituted indolinones with kinase inhibitory activity
04/08/2003US6545030 1-heterocycle substituted diarylamines
04/08/2003US6545020 Farnesyl Protein transferase inhibitors with in vivo radiosensitizing properties
04/08/2003US6545011 PARP (poly(adenosine 5'-diphospho-ribose) polymerase) inhibitors
04/08/2003US6545005 Mediators of hedgehog signaling pathways, compositions and uses related thereto
04/08/2003US6545004 Treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
04/08/2003US6545003 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
04/08/2003US6545002 Treating asthma, diarrhea, insulin resistance, diabetes, ischemia/reprefusion injuries, diabetic retinopathy or hyperbaric oxygen-induced retinopathy
04/08/2003US6544995 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric G protein
04/08/2003US6544991 Compositions and methods for treating bacterial infections
04/08/2003US6544988 Tyrosine kinase inhibitors
04/08/2003US6544979 Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents
04/08/2003US6544969 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin D compounds
04/08/2003US6544962 Methods for treating cellular proliferative disorders
04/08/2003US6544957 Histone acetylase inhibitor
04/08/2003US6544955 Method of sensitizing tumor cells with adenovirus E1A
04/08/2003US6544948 ΔP62, variants thereof, amino acid sequences coding therefor and their uses in gene therapy for cancer
04/08/2003US6544784 Multiple-tumor aberrant growth genes
04/08/2003US6544759 Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
04/08/2003US6544758 Methods for expressing endostatin protein
04/08/2003US6544560 Positioning a plurality of like substrates in sea water, growing the organism on the plurality of substrates, harvesting the grown organism, and extracting the pharmaceutical from the harvested organism
04/08/2003US6544544 Compound which disrupts microtubule function and polymeric carrier, with proviso that polymeric carrier is not a capsule
04/08/2003US6544518 Vaccines
04/08/2003US6544514 Compositions comprising, as the main ingredient, allogenic activated-C4+ cells and method for producing and using the same
04/08/2003US6544510 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
04/08/2003US6544509 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
04/08/2003US6544508 Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799)
04/08/2003US6544507 Anti-neoplastic viral agents
04/08/2003US6544193 Noninvasive measurement of chemical substances
04/08/2003CA2254152C New metalloprotease inhibitors, their preparation process and the pharmaceutical compositions which use them
04/08/2003CA2184584C Vascular endothelial growth factor 2
04/08/2003CA2127470C Methods and compositions for diagnosing cat scratch disease and bacillary angiomatosis
04/08/2003CA2097824C Functionalized vinyl azoles and their use
04/08/2003CA2096833C Method for preparing taxane derivatives, novel derivatives thereby obtained and pharmaceutical compositions containing same
04/08/2003CA2065849C Vitamin d analogues
04/07/2003WO2002032866A1 (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists
04/03/2003WO2003027632A2 Use of isogenic human cancer cells for high-throughput screening and drug discovery
04/03/2003WO2003027322A2 Hepatocellular carcinoma-related genes and polypeptides, and method for detecting hepatocellular carcinomas
04/03/2003WO2003027319A1 Aptamers containing sequences of nucleic acids or nucleic acid analogues bound homologously, or in novel complexes
04/03/2003WO2003027285A1 Dna sequences for human angiogenesis genes
04/03/2003WO2003027282A1 Adamts-15, -16, -17, -18 and -19
04/03/2003WO2003027263A2 Proteins associated with cell growth, differentiation, and death
04/03/2003WO2003027248A2 Antibody inhibitors of gdf-8 and uses thereof
04/03/2003WO2003027228A2 Receptors and membrane-associated proteins
04/03/2003WO2003027169A1 Material consisting of at least a biodegradable polymer and cyclodextrins
04/03/2003WO2003027144A1 ENZYME PHOSPHORYLATING Ser46 OF p53
04/03/2003WO2003027143A2 Gene and protein relating to hepatocellular carcinoma
04/03/2003WO2003027118A1 Pharmaceutically acceptable salts of 20(s)-camptothecins
04/03/2003WO2003027116A2 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
04/03/2003WO2003027115A1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
04/03/2003WO2003027114A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
04/03/2003WO2003027113A1 1,6-naphthyridine derivatives as antidiabetics
04/03/2003WO2003027112A1 1, 8-naphthyridine derivatives as antidiabetics
04/03/2003WO2003027111A1 Chemical compounds
04/03/2003WO2003027109A1 3-(heteroarylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
04/03/2003WO2003027108A1 Heterocyclic derivatives and their use as hypoglycaemic and hypolipidemic agents
04/03/2003WO2003027107A1 Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
04/03/2003WO2003027105A1 Substituted 3-pyridyl thiophenes as c17,20 lyase inhibitors
04/03/2003WO2003027102A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
04/03/2003WO2003027101A1 Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors
04/03/2003WO2003027100A1 Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
04/03/2003WO2003027098A1 Benzimidazole compound, process for producing the same, and use thereof
04/03/2003WO2003027096A1 Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
04/03/2003WO2003027095A1 Substituted 3-pyridyl tetrazoles as steroid c17,20 lyase inhibitors
04/03/2003WO2003027094A2 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
04/03/2003WO2003027093A1 Chemical compounds
04/03/2003WO2003027090A2 Bicyclic heterocycles as rxr ligands
04/03/2003WO2003027085A2 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
04/03/2003WO2003027080A1 3-substituted-4-pyrimidone derivatives
04/03/2003WO2003027076A2 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
04/03/2003WO2003027075A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
04/03/2003WO2003027074A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders
04/03/2003WO2003027069A1 Preparation and use of pyrrole derivatives for treating obesity
04/03/2003WO2003027058A1 Sphingolipids
04/03/2003WO2003026744A1 The use of epothilones and analogs in conjunction with ophthalmic surgery
04/03/2003WO2003026718A1 Coated implantable medical device
04/03/2003WO2003026701A1 Transporting of taxoid derivatives through the blood brain barrier
04/03/2003WO2003026696A1 Method of controlling proliferation of cancer cells and cell death
04/03/2003WO2003026691A2 Use of hmgb1 for the activation of dendritic cells
04/03/2003WO2003026686A1 Potentiating the therapeutic effects of interferons
04/03/2003WO2003026683A1 Health caring product for enhancing immunity and delaying aging
04/03/2003WO2003026673A1 Modulation of vitamin storage
04/03/2003WO2003026666A1 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
04/03/2003WO2003026665A1 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
04/03/2003WO2003026664A1 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
04/03/2003WO2003026663A1 Process for making substituted pyrazoles
04/03/2003WO2003026650A1 3-(heteroarylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
04/03/2003WO2003026648A1 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
04/03/2003WO2003026647A1 Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
04/03/2003WO2003026645A1 Tetrapeptide derivative crystals
04/03/2003WO2003026643A2 Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
04/03/2003WO2003026642A1 Freeze-dried pharmaceutical preparation
04/03/2003WO2003026590A2 Biological control of nanoparticles
04/03/2003WO2003026581A2 Pharmaceutical compositions and methods for treating cancer
04/03/2003WO2003026574A2 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
04/03/2003WO2003026570A2 Reduced toxicity cisplatin formulations and methods for using the same
04/03/2003WO2003026568A2 Androstanes as androgen receptor modulators
04/03/2003WO2003026563A2 Conjugated anti-psychotic drugs and uses thereof
04/03/2003WO2003026490A2 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
04/03/2003WO2003006104A3 Lymphatic endothelial cells materials and methods
1 ... 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 ... 2211